- Abstract Number: 1304
2D and 3D Measurements of Osteoarthritis Joint Space Width Have Good Agreement in Radiographically Normal Knees but Poor Agreement with Advancing Kellgren-Lawrence Grade: Data from the Osteoarthritis Initiative
- Abstract Number: 1557
3-D Explant Method Facilitates the Study of Lymphocytes in Synovium and Reveals a Population of Resident Memory-like T Cells in Rheumatoid Arthritis
- Abstract Number: 768
7-Year Safety and Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus
- Abstract Number: 164
99mtc-Hdp Digital Blood Flow Scintigraphy for Assessment of Raynaud Phenomenon Associated with Hand-Arm Vibration Syndrome
- Abstract Number: 909
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
- Abstract Number: 1651
A Case Series on Patients on Tofacitinib in Combination with a Biologic
- Abstract Number: 2018
A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
- Abstract Number: 1212
A Combined Large Scale Meta-Analysis Identifies COG6 As a Novel Shared Risk Locus for Rheumatoid Arthritis and Systemic Lupus Erythematosus
- Abstract Number: 2973
A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
- Abstract Number: 332
A Comparison of Electronic and Manual Fracture Risk Assessment Tools in Screening US Veterans at Risk for Osteoporosis
- Abstract Number: 2911
A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients
- Abstract Number: 2601
A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference
- Abstract Number: 2014
A Deep Insight into Causes and Predictors of Death in Systemic Sclerosis
- Abstract Number: 2240
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
- Abstract Number: 1233
A Descriptive Analysis of Real-World Treatment Patterns of Innovator Infliximab (Remicade) and Biosimilar Infliximab in a Treatment NaïVe Turkish Rheumatologic Disease Population
2016 ACR/ARHP Annual Meeting
November 11-16, 2016 in Washington, DC